Penn Wealth Publishing

2021.01.10 Penn Wealth Report Vol 9 Issue 01

Issue link: https://hub.pennwealth.com/i/1334662

Contents of this Issue

Navigation

Page 19 of 35

20 penn wealth Report volume 9 issue 01 10 Jan 2021 Penn Wealth Report Copyright 2021. All Rights Reserved. investment intelligence Actions we have taken at the Penn Trading Desk, plus a look at what other Wall Street analysts have to say... Trading Desk To remain on top of all recom- mended trades as they happen, be sure and subscribe to our Twitter feed @ PennWealth. All trade details can be found at the Penn Wealth Trading Desk. Penn: OPen nAT in inTrePid (29 Oct 20) We have traded Bermuda- based maritime shipper Nordic American Tankers since the late 1990s, and we have an excellent sense for when it is undervalued. Oil futures are currently sitting at $35 per barrel on dour senti- ment based on the second wave of Covid cases. Investors are buying into the false narrative being foisted by the press. We opened NAT @ $2.80 in the Intrepid. We believe fair value is $5 per share. Penn: OPen rGr in inTrePid (30 Oct 20) Founded in 1949, $1.1 billion Sturm Ruger & Co. is a leading American manufacturer of rifles, pistols, and revolv- ers. With a PE ratio of 18, this small-cap industrials company has rock-solid annual income, a strong balance sheet, and a faithful customer base. We opened RGR in the Intrepid at $66.72 on 30 Oct 20 with an initial target price of $80 and no stop-loss. Penn: OPen BWA in GlOBAl leAders (03 Nov 20) For investors looking for an ancillary play on the clean air and electric vehicle movement, look no further than auto parts maker BorgWarner. The $8 billion firm recently closed its acquisition of Delphi, adding electric and electronic components to its electric motors and driveline technologies. We opened BWA in the Global Leaders Club at $36.57 with an initial target price of $55, which would represent a 50% spike. Penn: ClOse ABBV in GlOBAl leAders (12 Nov 20) We are closing AbbVie ABBV $97 in the Global Leaders Club and replacing with GlaxoSmithKline. AbbVie is an excel- lent biotech with plenty of room for growth, but based on pipeline outlooks for both companies we are taking our 45% profit off the table and making the switch. We pur- chased ABBV shortly after Allergan pick-up. Penn: OPen GsK in GlOBAl leAders (12 Nov 20) GlaxoSmithKline GSK $38 is one of the world's largest pharma companies by sales. It is a leader in the respiratory, oncology, antiviral, and vaccine arenas. It provides a strong, 5.4% dividend yield, is about 40% undervalued by our estimate, and adds to the international portion of a portfolio. Penn: ClOse M in inTrePid (23 Nov 20) On 18 May we added Macy's (M $10) to the Intrepid @ $5.55/share. We took advantage of a double-digit jump on 23 Nov to close our position @ 10.09/ share for an 82% short-term gain. It may well go higher, but we want to redeploy the capital elsewhere. Penn: ClOse TCO in siP (29 Dec 20) After a tumultuous courtship, Simon Property Group finally closed on their acquisition of Taubman Centers. Our TCO investors were paid $43 per share in cash. We purchased TCO shares after SPG pulled out of the deal in June, sending shares tumbling 25%. Penn: OPen PAVe in dGs (15 Jan 21) As if the government (tax- payer) money hasn't already been flowing with abandon, massive infra- structure spending is now all but guaranteed over the coming two years. Fortuitously, the Global X US Infrastructure Development ETF (PAVE $22) should not only be able to take full advantage of this condition, it also happens to hold a number of our best small- and mid-cap industrial ideas. Adding PAVE to the Dynamic Growth Strategy at $22.57/share. Penn: Add TO eMB hOldinG (19 Jan 21) We are adding to our Emerging Markets Bond ETF (EMB $113) in the Strategic Income Portfolio. e content of this report reflects the personal views, opinions, and research of Penn Wealth Publishing. While measures are taken to help assure the accuracy of data, no guarantees can be made and the firm is not liable for any losses incurred by subscribers. is is not a solicitation to buy. Always con- sult your investment professional before investing any money.

Articles in this issue

Links on this page

Archives of this issue

view archives of Penn Wealth Publishing - 2021.01.10 Penn Wealth Report Vol 9 Issue 01